What Is The Difference Between Wegovy And Mounjaro? Helping Scotland Patients Decide

If you have been researching weight loss injections, you have likely come across both Wegovy and Mounjaro. They are both once-weekly injectable medications used for weight management, both require a prescription, and both are available privately across Scotland. However, the similarities largely end there.

Understanding how they differ can help you have a more informed conversation with your prescriber. At CarePoint Pharmacy, we help patients across Scotland choose the most clinically appropriate option based on their health history and goals. Contact us to discuss your options or book a consultation today.

Here is what this guide covers:

• How Wegovy and Mounjaro work differently
• A full dose comparison
• The pros and cons of each medication
• Who may be better suited to each
• Whether age or gender plays a role in suitability

How Do They Work?

Wegovy contains semaglutide and works as a GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone, which reduces appetite, slows gastric emptying and signals fullness to the brain after eating smaller quantities.

Mounjaro contains tirzepatide and operates through a dual mechanism, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This additional hormone pathway is widely considered to be responsible for Mounjaro’s stronger average weight loss outcomes in clinical trials.

In short, Wegovy acts on one hormone pathway. Mounjaro acts on two.

Dose Comparison

It is also worth noting that Novo Nordisk has been developing a higher-strength 7.2mg dose of Wegovy, which demonstrated significantly greater weight loss in clinical trials compared to the standard 2.4mg dose. This higher dose is not yet widely available in the UK, but it may offer an important additional option for patients who reach the current maintenance dose without achieving sufficient results.

Wegovy: Pros

• Longer clinical track record with an extensively documented safety profile
• Strong cardiovascular outcomes, making it particularly relevant for patients with existing heart disease risk factors
• Widely studied through the STEP trial programme with robust real-world evidence
• Generally priced lower than Mounjaro in private settings across Scotland
• May be better tolerated by patients who are more sensitive to appetite suppression effects
• Well-established prescribing guidelines within UK clinical practice

Wegovy: Cons

• Single hormone pathway typically produces lower average weight loss compared to Mounjaro
• Nausea and gastrointestinal side effects are among the most commonly reported, particularly during dose escalation
• Some patients reach a plateau before achieving the full maintenance dose
• UK supply has been affected by shortages in recent years, though availability has improved
• The 2.4mg ceiling may feel limiting for patients who require a stronger effect

Mounjaro: Pros

• Dual GIP and GLP-1 mechanism is associated with greater average weight loss in clinical trials
• May provide stronger appetite and food craving control for patients who struggle with dietary adherence
• Beneficial metabolic effects on insulin sensitivity, making it a strong option for patients with type 2 diabetes or insulin resistance
• A wider dose range allows for more flexible titration based on individual response and tolerance

Mounjaro: Cons

• Generally more expensive than Wegovy in private settings
• Newer to the UK market, meaning a shorter long-term safety record compared to semaglutide
• The dual hormone mechanism may produce stronger initial side effects for some patients during the early weeks of treatment
• Cardiovascular outcome data, while promising, is less mature than the established evidence base for Wegovy
• Not suitable for all patients and contraindications must be carefully reviewed during consultation

Who May Be Better Suited To Wegovy?

Wegovy may be the more appropriate starting point for patients who:

• Are new to injectable weight loss medications and want to begin with a well-established, widely used option
• Have a personal or family history of cardiovascular disease
• Are cost-conscious, as Wegovy is typically the more affordable of the two privately
• Have previously responded well to GLP-1 receptor agonist treatments
• Prefer a longer real-world track record before starting a newer medication
• Have a moderate amount of weight to lose and are looking for a steady, clinically supported approach

Who May Be Better Suited To Mounjaro?

Mounjaro may be worth considering for patients who:

• Have a higher starting BMI and are likely to benefit from the stronger average weight loss outcomes associated with tirzepatide
• Have type 2 diabetes or clinically significant insulin resistance, as the GIP pathway supports glucose regulation alongside weight reduction
• Have previously tried a GLP-1 medication such as Wegovy or Ozempic with limited results
• Experience persistent food cravings and find appetite control particularly difficult
• Are looking for the greatest possible weight loss outcome and are willing to accept a higher monthly cost
• Have been assessed as clinically appropriate for a dual-mechanism approach following a full consultation

Does Age Or Gender Make A Difference?

There is no single clinical rule that determines suitability based on age or gender alone, but there are several relevant considerations.

Age:

• Both medications are licensed for adults aged 18 and over in the UK
• Neither is currently licensed for weight management in patients under 18
• Older patients may require closer monitoring during dose escalation due to a greater likelihood of existing health conditions, polypharmacy or reduced kidney function
• Age-related changes in metabolism may affect the rate of weight loss, but both medications remain effective across adult age groups

Gender:

• Clinical trial data does not indicate a significant difference in overall efficacy between males and females for either medication
• Hormonal factors can influence weight loss response, and this is worth discussing during consultation
• Patients with polycystic ovary syndrome (PCOS) may find that Mounjaro’s insulin-sensitising properties offer additional metabolic benefit beyond weight loss alone
• Patients who are perimenopausal or postmenopausal may find weight loss more challenging due to hormonal changes; both medications can still be effective, but expectations should be discussed openly with a prescriber
• Neither medication is suitable during pregnancy or breastfeeding

Choosing The Right Option With CarePoint Pharmacy

The decision between Wegovy and Mounjaro should always be made with clinical guidance. Both are powerful, effective medications when used correctly and under proper supervision. The best option for you depends on your medical history, current health conditions, goals, tolerance and budget.

Our team supports patients across Scotland through a structured assessment process before any prescription is issued, ensuring treatment is appropriate, safe and well-supported from the outset. Explore our full weight management services or read our detailed Wegovy vs Mounjaro comparison for further information.

Book A Consultation At CarePoint Pharmacy

Contact us or visit one of our clinics to discuss which medication may be right for you:

Airdrie:
45 Main Street, Airdrie, ML6 9SG
Tel: 01236 752900

Auchinleck:
178 Main Street, Auchinleck, KA18 2AX
Tel: 01290 421944

Or book your consultation online today.